MAP2K7 and head and neck squamous cell carcinoma: For example, enhanced TAZ expression was shown to enhance the resistance of HNSCC cells to chemotherapy [75], and YAP was reported to mediate HNSCC resistance to the MEK inhibitor trametinib [100].